Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for COVID-19 Hospitalization and Discharge
NCT04508439Unknown
- Sponsor
- Hospital Regional de Alta Especialidad de Ixtapaluca
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by Hospital Regional de Alta Especialidad de Ixtapaluca. Primary endpoint: Time on ventilatory support at 30 days. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04508439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508439.